Lilly pays $1.27B to become partner in U.S.-Russian collaboration; Galapagos starts PhII for RA candidate;

 @FierceBiotech: AZ's zibotentan flunks late-stage prostate cancer trial. Article | Follow @FierceBiotech

> Eli Lilly has paid $1.27 billion to become the founding private partner of a new partnership between the US and Russia designed to encourage collaboration on shared priorities in health related research. News

> Galapagos has started a Phase II clinical study for the company's flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis (RA). In this clinical trial, the safety and efficacy of this novel candidate drug will be tested in RA patients. Galapagos plans to announce interim results by the middle of next year and complete the trial by the end of 2011. Galapagos release

> Dynavax Technologies today announced that the data safety monitoring board established for the company's two ongoing Phase III trials for HEPLISAV has completed the third of its planned safety assessments. Dynavax release

> Inovio Pharmaceuticals announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa and South America. Inovio release

> Oncolytics Biotech has been granted U.S. Patent, #7,803,385 titled "Reoviruses Having Modified Sequences." The patent claims cover methods for making and using modified reoviruses, and pharmaceutical compositions that include modified reoviruses. Oncolytics release

> AstraZeneca Pharma India announced that it will not move ahead with its plans to delist the company, as its shareholders voted against the proposal. News

> Add pine-bark extract to the list of dietary supplements that don't live up to their promises of improved health. A new study from the Stanford University School of Medicine shows that pine-bark extract had no effect in lowering blood pressure or reducing other risk factors for heart disease. Stanford release

And Finally... Virginia Commonwealth University School of Medicine and VCU Massey Cancer Center researchers have shown that the impotence drug Viagra, in combination with doxorubicin, a powerful anti-cancer drug, enhances its anti-tumor efficacy in prostate cancer while alleviating the damage to the heart at the same time. VCU release